Physician profile
Alex Wu
NPI 1770978231
$2,818.46
in general payments reported to CMS, 2019-2025
27 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.01 · 2022: $279 · 2023: $465 · 2024: $866 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.77 |
| Education | $319.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $472.74 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $288.15 | 2024-2025 | Xtandi, Vyloy |
| Daiichi Sankyo INC. | $191.76 | 2022-2025 | Enhertu, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.23 | 2022-2025 | Gilotrif |
| Eisai INC. | $189.16 | 2022-2024 | |
| Sobi, INC | $153.90 | 2022-2025 | |
| Stemline Therapeutics INC. | $141.89 | 2023-2024 | Orserdu |
| Shield Therapeutics INC | $140.80 | 2023-2025 | Accrufer |
| Puma Biotechnology, INC. | $138.97 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.02 | 2023-2025 | |
| Celgene Corporation | $122.34 | 2024-2025 | Reblozyl |
| Janssen Biotech, INC. | $116.00 | 2025 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $104.22 | 2024-2025 | Lynparza, Calquence, Enhertu |
| Agios Pharmaceuticals, INC. | $79.98 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $60.44 | 2024-2025 | Zejula, Jemperli |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.20 | 2024-2025 | Opdivo |
| Geron Corporation | $40.50 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2023 | Alunbrig |
| Merck Sharp & Dohme LLC | $25.00 | 2023 | Keytruda |
| Genzyme Corporation | $23.07 | 2025 | |
| Lilly USA, LLC | $22.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.33 | 2025 | |
| Amgen INC. | $20.00 | 2023 | Lumakras |
| Beigene USA, INC. | $19.88 | 2025 | Brukinsa |
| Coherus Oncology, INC. | $16.25 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.03 | 2025 | Danziten |
| Array Biopharma INC | $14.00 | 2023 | Braftovi, Lorbrena, Xalkori |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.